NASDAQ:ACIU

AC Immune Competitors

$6.87
-0.04 (-0.58 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.71
Now: $6.87
$7.09
50-Day Range
$6.91
MA: $7.68
$8.08
52-Week Range
$4.42
Now: $6.87
$13.00
Volume189,214 shs
Average Volume923,648 shs
Market Capitalization$494.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.82

Competitors

AC Immune (NASDAQ:ACIU) Vs. NGM, MORF, KURA, MCRB, MDGL, and MGNX

Should you be buying ACIU stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to AC Immune, including NGM Biopharmaceuticals (NGM), Morphic (MORF), Kura Oncology (KURA), Seres Therapeutics (MCRB), Madrigal Pharmaceuticals (MDGL), and MacroGenics (MGNX).

NGM Biopharmaceuticals (NASDAQ:NGM) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Insider and Institutional Ownership

49.6% of NGM Biopharmaceuticals shares are owned by institutional investors. Comparatively, 27.7% of AC Immune shares are owned by institutional investors. 50.4% of NGM Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for NGM Biopharmaceuticals and AC Immune, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
NGM Biopharmaceuticals00523.29
AC Immune00103.00

NGM Biopharmaceuticals currently has a consensus price target of $39.1111, indicating a potential upside of 53.80%. AC Immune has a consensus price target of $16.00, indicating a potential upside of 132.90%. Given AC Immune's higher possible upside, analysts plainly believe AC Immune is more favorable than NGM Biopharmaceuticals.

Volatility & Risk

NGM Biopharmaceuticals has a beta of 1.97, indicating that its share price is 97% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Earnings and Valuation

This table compares NGM Biopharmaceuticals and AC Immune's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NGM Biopharmaceuticals$103.54 million18.84$-42,790,000.00($0.85)-29.92
AC Immune$111.75 million4.42$45.74 million$0.6011.45

AC Immune has higher revenue and earnings than NGM Biopharmaceuticals. NGM Biopharmaceuticals is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares NGM Biopharmaceuticals and AC Immune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
NGM Biopharmaceuticals-91.64%-29.47%-25.58%
AC Immune-392.56%-23.88%-21.85%

Summary

NGM Biopharmaceuticals beats AC Immune on 8 of the 15 factors compared between the two stocks.

AC Immune (NASDAQ:ACIU) and Morphic (NASDAQ:MORF) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, earnings, institutional ownership and valuation.

Analyst Ratings

This is a breakdown of recent ratings for AC Immune and Morphic, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AC Immune00103.00
Morphic00203.00

AC Immune currently has a consensus target price of $16.00, indicating a potential upside of 132.90%. Morphic has a consensus target price of $63.3333, indicating a potential upside of 6.71%. Given AC Immune's higher possible upside, research analysts clearly believe AC Immune is more favorable than Morphic.

Profitability

This table compares AC Immune and Morphic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AC Immune-392.56%-23.88%-21.85%
MorphicN/A-36.62%-20.69%

Risk and Volatility

AC Immune has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, Morphic has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500.

Institutional and Insider Ownership

27.7% of AC Immune shares are owned by institutional investors. Comparatively, 61.5% of Morphic shares are owned by institutional investors. 39.5% of Morphic shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares AC Immune and Morphic's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AC Immune$111.75 million4.42$45.74 million$0.6011.45
Morphic$16.98 million113.42$-43,330,000.00($2.69)-22.06

AC Immune has higher revenue and earnings than Morphic. Morphic is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Summary

Morphic beats AC Immune on 7 of the 13 factors compared between the two stocks.

AC Immune (NASDAQ:ACIU) and Kura Oncology (NASDAQ:KURA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Institutional and Insider Ownership

27.7% of AC Immune shares are owned by institutional investors. Comparatively, 94.7% of Kura Oncology shares are owned by institutional investors. 11.0% of Kura Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares AC Immune and Kura Oncology's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AC Immune$111.75 million4.42$45.74 million$0.6011.45
Kura OncologyN/AN/A$-63,140,000.00($1.51)-18.92

AC Immune has higher revenue and earnings than Kura Oncology. Kura Oncology is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings for AC Immune and Kura Oncology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AC Immune00103.00
Kura Oncology011002.91

AC Immune currently has a consensus target price of $16.00, suggesting a potential upside of 132.90%. Kura Oncology has a consensus target price of $39.5455, suggesting a potential upside of 38.42%. Given AC Immune's stronger consensus rating and higher possible upside, equities research analysts clearly believe AC Immune is more favorable than Kura Oncology.

Risk and Volatility

AC Immune has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 2.15, suggesting that its share price is 115% more volatile than the S&P 500.

Profitability

This table compares AC Immune and Kura Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AC Immune-392.56%-23.88%-21.85%
Kura OncologyN/A-30.96%-28.02%

Summary

AC Immune beats Kura Oncology on 8 of the 13 factors compared between the two stocks.

Seres Therapeutics (NASDAQ:MCRB) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Risk and Volatility

Seres Therapeutics has a beta of 4.07, meaning that its stock price is 307% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Valuation & Earnings

This table compares Seres Therapeutics and AC Immune's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seres Therapeutics$34.51 million54.60$-70,280,000.00($1.20)-17.15
AC Immune$111.75 million4.42$45.74 million$0.6011.45

AC Immune has higher revenue and earnings than Seres Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Seres Therapeutics and AC Immune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seres Therapeutics-385.22%-2,867.98%-51.24%
AC Immune-392.56%-23.88%-21.85%

Insider & Institutional Ownership

94.3% of Seres Therapeutics shares are owned by institutional investors. Comparatively, 27.7% of AC Immune shares are owned by institutional investors. 4.8% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Seres Therapeutics and AC Immune, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seres Therapeutics01602.86
AC Immune00103.00

Seres Therapeutics currently has a consensus price target of $38.1667, indicating a potential upside of 85.46%. AC Immune has a consensus price target of $16.00, indicating a potential upside of 132.90%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than Seres Therapeutics.

Summary

AC Immune beats Seres Therapeutics on 8 of the 14 factors compared between the two stocks.

Madrigal Pharmaceuticals (NASDAQ:MDGL) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Institutional & Insider Ownership

74.2% of Madrigal Pharmaceuticals shares are held by institutional investors. Comparatively, 27.7% of AC Immune shares are held by institutional investors. 41.9% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Madrigal Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Madrigal Pharmaceuticals and AC Immune, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Madrigal Pharmaceuticals03702.70
AC Immune00103.00

Madrigal Pharmaceuticals currently has a consensus price target of $167.60, indicating a potential upside of 43.22%. AC Immune has a consensus price target of $16.00, indicating a potential upside of 132.90%. Given AC Immune's stronger consensus rating and higher possible upside, analysts clearly believe AC Immune is more favorable than Madrigal Pharmaceuticals.

Earnings and Valuation

This table compares Madrigal Pharmaceuticals and AC Immune's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Madrigal PharmaceuticalsN/AN/A$-83,950,000.00($5.45)-21.47
AC Immune$111.75 million4.42$45.74 million$0.6011.45

AC Immune has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Madrigal Pharmaceuticals and AC Immune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Madrigal PharmaceuticalsN/A-47.64%-43.21%
AC Immune-392.56%-23.88%-21.85%

Summary

AC Immune beats Madrigal Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

MacroGenics (NASDAQ:MGNX) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

Profitability

This table compares MacroGenics and AC Immune's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MacroGenics-204.31%-65.84%-49.41%
AC Immune-392.56%-23.88%-21.85%

Earnings and Valuation

This table compares MacroGenics and AC Immune's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MacroGenics$64.19 million29.11$-151,810,000.00($3.16)-9.86
AC Immune$111.75 million4.42$45.74 million$0.6011.45

AC Immune has higher revenue and earnings than MacroGenics. MacroGenics is trading at a lower price-to-earnings ratio than AC Immune, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

MacroGenics has a beta of 2.4, suggesting that its share price is 140% more volatile than the S&P 500. Comparatively, AC Immune has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500.

Institutional & Insider Ownership

95.8% of MacroGenics shares are owned by institutional investors. Comparatively, 27.7% of AC Immune shares are owned by institutional investors. 9.0% of MacroGenics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for MacroGenics and AC Immune, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MacroGenics11902.73
AC Immune00103.00

MacroGenics presently has a consensus target price of $33.30, suggesting a potential upside of 6.87%. AC Immune has a consensus target price of $16.00, suggesting a potential upside of 132.90%. Given AC Immune's stronger consensus rating and higher possible upside, analysts plainly believe AC Immune is more favorable than MacroGenics.

Summary

AC Immune beats MacroGenics on 8 of the 14 factors compared between the two stocks.


AC Immune Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
NGM Biopharmaceuticals logo
NGM
NGM Biopharmaceuticals
1.8$25.43-3.8%$1.95 billion$103.54 million-19.12Gap Down
MORF
Morphic
1.1$59.35-3.0%$1.93 billion$16.98 million-38.04Insider Selling
Kura Oncology logo
KURA
Kura Oncology
1.6$28.57-0.8%$1.89 billionN/A-17.53
Seres Therapeutics logo
MCRB
Seres Therapeutics
1.7$20.58-0.1%$1.88 billion$34.51 million-17.59News Coverage
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$117.02-0.4%$1.88 billionN/A-10.57
MacroGenics logo
MGNX
MacroGenics
1.2$31.16-1.3%$1.87 billion$64.19 million-9.96
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
1.6$5.96-2.7%$1.79 billion$1.63 billion14.54News Coverage
Pandion Therapeutics logo
PAND
Pandion Therapeutics
1.0$60.05-0.0%$1.77 billion$970,000.000.00
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.4$37.94-0.1%$1.77 billion$14.87 million-14.16News Coverage
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$48.93-21.0%$1.72 billionN/A0.00Insider Buying
Gap Down
Cytokinetics logo
CYTK
Cytokinetics
1.7$24.16-0.1%$1.72 billion$26.87 million-12.65
FibroGen logo
FGEN
FibroGen
1.8$18.57-1.3%$1.70 billion$256.58 million-7.11Analyst Downgrade
High Trading Volume
Unusual Options Activity
Analyst Revision
News Coverage
Cassava Sciences logo
SAVA
Cassava Sciences
0.9$41.57-1.3%$1.66 billionN/A-173.21
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.99-7.6%$1.65 billion$2.34 million-10.17Gap Down
Myovant Sciences logo
MYOV
Myovant Sciences
1.3$18.15-1.2%$1.65 billionN/A-6.46Insider Selling
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.4$35.26-6.0%$1.64 billionN/A0.00Insider Selling
News Coverage
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.8$10.19-1.5%$1.64 billion$428.41 million14.77
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$12.80-1.3%$1.63 billion$320,000.00-8.71News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Gap Down
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Gap Down
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95Gap Down
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
Gap Down
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77High Trading Volume
Unusual Options Activity
News Coverage
Gap Up
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00Gap Down
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43Gap Down
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00Gap Down
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58-0.5%$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38-8.0%$1.15 billionN/A-8.88News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.